RT Journal Article
T1 Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients.
A1 Comino, Isabel
A1 Fernández-Bañares, Fernando
A1 Esteve, María
A1 Ortigosa, Luís
A1 Castillejo, Gemma
A1 Fambuena, Blanca
A1 Ribes-Koninckx, Carmen
A1 Sierra, Carlos
A1 Rodríguez-Herrera, Alfonso
A1 Salazar, José Carlos
A1 Caunedo, Ángel
A1 Marugán-Miguelsanz, J M
A1 Garrote, José Antonio
A1 Vivas, Santiago
A1 Lo Iacono, Oreste
A1 Nuñez, Alejandro
A1 Vaquero, Luis
A1 Vegas, Ana María
A1 Crespo, Laura
A1 Fernández-Salazar, Luis
A1 Arranz, Eduardo
A1 Jiménez-García, Victoria Alejandra
A1 Antonio Montes-Cano, Marco
A1 Espín, Beatriz
A1 Galera, Ana
A1 Valverde, Justo
A1 Girón, Francisco José
A1 Bolonio, Miguel
A1 Millán, Antonio
A1 Martínez Cerezo, Francesc
A1 Guajardo, César
A1 Alberto, José Ramón
A1 Rosinach, Mercé
A1 Segura, Verónica
A1 León, Francisco
A1 Marinich, Jorge
A1 Muñoz-Suano, Alba
A1 Romero-Gómez, Manuel
A1 Cebolla, Ángel
A1 Sousa, Carolina
K1 Enfermedad celíaca
K1 Dieta sin gluten
K1 Ensayo de inmunoadsorción enzimática
K1 Proteínas de unión al GTP
K1 Gliadina
K1 Glútenes
K1 Humanos
K1 Inmunoglobulina A
K1 Masculino
K1 Cooperación del paciente
K1 Péptidos
K1 Estudios prospectivos
K1 Encuestas y cuestionarios
K1 Transglutaminasas
AB OBJECTIVESTreatment for celiac disease (CD) is a lifelong strict gluten-free diet (GFD). Patients should be followed-up with dietary interviews and serology as CD markers to ensure adherence to the diet. However, none of these methods offer an accurate measure of dietary compliance. Our aim was to evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of GFD adherence in CD patients and compare it with traditional methods of GFD monitoring.METHODSWe performed a prospective, nonrandomized, multicenter study including 188 CD patients on GFD and 84 healthy controls. Subjects were given a dietary questionnaire and fecal GIP quantified by enzyme-linked immunosorbent assay (ELISA). Serological anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated gliadin peptide (anti-DGP) IgA antibodies were measured simultaneously.RESULTSOf the 188 celiac patients, 56 (29.8%) had detectable GIP levels in stools. There was significant association between age and GIP in stools that revealed increasing dietary transgressions with advancing age (39.2% in subjects ≥13 years old) and with gender in certain age groups (60% in men ≥13 years old). No association was found between fecal GIP and dietary questionnaire or anti-tTG antibodies. However, association was detected between GIP and anti-DGP antibodies, although 46 of the 53 GIP stool-positive patients were negative for anti-DGP.CONCLUSIONSDetection of gluten peptides in stools reveals limitations of traditional methods for monitoring GFD in celiac patients. The GIP ELISA enables direct and quantitative assessment of gluten exposure early after ingestion and could aid in the diagnosis and clinical management of nonresponsive CD and refractory CD. Trial registration number NCT02711397.
PB Nature Publishing Group
SN 0002-9270
YR 2016
FD 2016-10-11
LK http://hdl.handle.net/10668/2726
UL http://hdl.handle.net/10668/2726
LA en
NO Comino I, Fernández-Bañares F, Esteve M, Ortigosa L, Castillejo G, Fambuena B, et al. Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. Am. J. Gastroenterol.. 2016                         ; 111(10):1456-1465
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 8, 2025